Associated Banc Corp Increases Stake in Eli Lilly and Company $LLY

Associated Banc Corp boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 59,063 shares of the company's stock after purchasing an additional 1,027 shares during the period. Eli Lilly and Company comprises about 1.4% of Associated Banc Corp's investment portfolio, making the stock its 12th biggest position. Associated Banc Corp's holdings in Eli Lilly and Company were worth $54,324,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of LLY. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC increased its position in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after purchasing an additional 16 shares during the last quarter. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at $30,000. Finally, Maseco LLP lifted its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after purchasing an additional 28 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Guggenheim reiterated a "buy" rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an "overweight" rating in a report on Monday, July 6th. The Goldman Sachs Group reiterated a "buy" rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Jefferies Financial Group increased their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a research report on Tuesday, June 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,263.41.

Eli Lilly and Company Stock Performance

NYSE LLY traded down $27.89 during mid-day trading on Friday, reaching $1,189.06. 2,008,208 shares of the stock were exchanged, compared to its average volume of 2,892,553. The company has a market capitalization of $1.12 trillion, a P/E ratio of 42.24, a P/E/G ratio of 1.47 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business's 50 day moving average is $1,098.66 and its 200-day moving average is $1,033.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same quarter in the previous year, the company earned $3.34 earnings per share. The company's quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 35.81 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.